2001 Meeting

WHO SHOULD ATTEND

ACKNOWLEDGMENTS

	PROGRAM OVERVIEW			Alzheimer's disease is a major health problem and the leading cause of dementia in the Americas, Europe and the Mediterranean countries. Although dementia studies in the Middle East are few, there is evidence that Alzheimer's disease may have high prevalence among the peoples of the Middle East. The progressive aging of the population of the Middle East makes this an issue worth attention. This conference will serve to focus attention on neurodegenerative disorders of the aged in the Middle East and to raise scientific, medical and social awareness concerning these disorders. ADDF's 9th Intl Conference on AD Drug Discovery Report from nico stanculescu on Vimeo.
	Clinical physicians, scientists, representatives of government and social agencies, representatives of pharmaceutical and biotechnological companies, and other health care professionals with an interest in the aging community of the Middle East are welcome. Attendance will be open to participants from all countries.
	This program has received financial support from the Institute for the Study of Aging, Inc. in New York City and the National Institutes of Health. Additional educational grants have been received from Novartis and GlaxoWellcome. Endorsement has been received by the World Federation of Neurology, Alzheimer's Disease International and the Pancyprian Association of Alzheimer's Disease.

Top